Niclosamide Induces PRX1 Stem Cell Proliferation
Summary
USPTO published Patent Application US20260108480A1 on April 23, 2026, filed September 25, 2023, covering methods of inducing proliferation of PRX1-expressing stem cells using niclosamide or its pharmaceutical derivatives. The application names Giuseppe Intini, Luigi Mancinelli, and Xue Hui Geng as inventors. CPC classifications include A61K 31/167, A61K 31/352, A61K 31/4709, and A61P 19/08.
“Described herein are methods of inducing proliferation of PRX1 expressing stem cells stem cells in a subject in need thereof, the method can include administering an effective amount of niclosamide, or a pharmaceutically acceptable salt, prodrug, or derivative thereof.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 193 changes logged to date.
What changed
USPTO published a patent application covering methods of inducing proliferation of PRX1-expressing stem cells through administration of niclosamide or its pharmaceutical salts, prodrugs, and derivatives. The application, filed September 25, 2023, was published April 23, 2026, naming Giuseppe Intini, Luigi Mancinelli, and Xue Hui Geng as inventors. Patent applicants and pharmaceutical researchers should note the therapeutic application of niclosamide in stem cell proliferation, which may indicate commercial or research opportunities in regenerative medicine using this anthelmintic compound.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR INDUCING PROLIFERATION OF STEM CELLS
Application US20260108480A1 Kind: A1 Apr 23, 2026
Inventors
Giuseppe INTINI, Luigi MANCINELLI, Xue Hui GENG
Abstract
Described herein are methods of inducing proliferation of PRX1 expressing stem cells stem cells in a subject in need thereof, the method can include administering an effective amount of niclosamide, or a pharmaceutically acceptable salt, prodrug, or derivative thereof.
CPC Classifications
A61K 31/167 A61K 31/352 A61K 31/4709 A61P 19/08
Filing Date
2023-09-25
Application No.
19114182
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.